1,191 results on '"Pappo, Alberto"'
Search Results
2. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.
- Author
-
Choy, Edwin, Connelly, Mary, Dry, Sarah, Ganjoo, Kristen, Gonzalez, Ricardo, Holder, Ashley, Homsi, Jade, Keedy, Vicki, Kelly, Ciara, Kim, Edward, Liebner, David, McCarter, Martin, McGarry, Sean, Mesko, Nathan, Meyer, Christian, Pappo, Alberto, Parkes, Amanda, Petersen, Ivy, Poppe, Matthew, Schuetze, Scott, Shabason, Jacob, Spraker, Matthew, Zimel, Melissa, Bergman, Mary, Sundar, Hema, Hang, Lisa, von Mehren, Margaret, Kane, John, Riedel, Richard, Sicklick, Jason, Pollack, Seth, Agulnik, Mark, Bui, Marilyn, and Carr-Ascher, Janai
- Subjects
Humans ,Gastrointestinal Stromal Tumors ,Receptor ,Platelet-Derived Growth Factor alpha ,Proto-Oncogene Proteins c-kit ,Mutation - Abstract
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.
- Published
- 2022
3. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
- Author
-
von Mehren, Margaret, Kane, John M, Agulnik, Mark, Bui, Marilyn M, Carr-Ascher, Janai, Choy, Edwin, Connelly, Mary, Dry, Sarah, Ganjoo, Kristen N, Gonzalez, Ricardo J, Holder, Ashley, Homsi, Jade, Keedy, Vicki, Kelly, Ciara M, Kim, Edward, Liebner, David, McCarter, Martin, McGarry, Sean V, Mesko, Nathan W, Meyer, Christian, Pappo, Alberto S, Parkes, Amanda M, Petersen, Ivy A, Pollack, Seth M, Poppe, Matthew, Riedel, Richard F, Schuetze, Scott, Shabason, Jacob, Sicklick, Jason K, Spraker, Matthew B, Zimel, Melissa, Hang, Lisa E, Sundar, Hema, and Bergman, Mary Anne
- Subjects
Biomedical and Clinical Sciences ,Health Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Orphan Drug ,Clinical Trials and Supportive Activities ,Pediatric Cancer ,Rare Diseases ,Cancer ,Clinical Research ,Pediatric ,Extremities ,Humans ,Medical Oncology ,Sarcoma ,Soft Tissue Neoplasms ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Health services and systems - Abstract
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.
- Published
- 2022
4. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer
- Author
-
Pearson, Andrew DJ, DuBois, Steven G., Macy, Margaret E., de Rojas, Teresa, Donoghue, Martha, Weiner, Susan, Knoderer, Holly, Bernardi, Ronald, Buenger, Vickie, Canaud, Guillaume, Cantley, Lewis, Chung, John, Fox, Elizabeth, Friend, John, Glade-Bender, Julia, Gorbatchevsky, Igor, Gore, Lia, Gupta, Abha, Hawkins, Douglas S., Juric, Dejan, Lang, Leigh Anna, Leach, Danielle, Liaw, Danny, Lesa, Giovanni, Ligas, Franca, Lindberg, Gavin, Lindberg, Wendy, Ludwinski, Donna, Marshall, Lynley, Mazar, Andrew, McDonough, Joe, Nysom, Karsten, Ours, Christopher, Pappo, Alberto, Parsons, D.William, Rosenfeld, Amy, Scobie, Nicole, Smith, Malcolm, Taylor, Danielle, Weigel, Brenda, Weinstein, Amy, Karres, Dominik, and Vassal, Gilles
- Published
- 2024
- Full Text
- View/download PDF
5. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A
- Author
-
Furman, Wayne L, McCarville, Beth, Shulkin, Barry L, Davidoff, Andrew, Krasin, Matthew, Hsu, Chia-Wei, Pan, Haitao, Wu, Jianrong, Brennan, Rachel, Bishop, Michael W, Helmig, Sara, Stewart, Elizabeth, Navid, Fariba, Triplett, Brandon, Santana, Victor, Santiago, Teresa, Hank, Jacquelyn A, Gillies, Stephen D, Yu, Alice, Sondel, Paul M, Leung, Wing H, Pappo, Alberto, and Federico, Sara M
- Subjects
Neuroblastoma ,Clinical Research ,Cancer ,Clinical Trials and Supportive Activities ,Rare Diseases ,Neurosciences ,Pediatric ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,6.2 Cellular and gene therapies ,Adolescent ,Age Factors ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Agents ,Immunological ,Antineoplastic Combined Chemotherapy Protocols ,Child ,Child ,Preschool ,Female ,Granulocyte-Macrophage Colony-Stimulating Factor ,Humans ,Induction Chemotherapy ,Infant ,Interleukin-2 ,Male ,Progression-Free Survival ,Prospective Studies ,Risk Assessment ,Risk Factors ,Time Factors ,Tumor Burden ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeWe evaluated whether combining a humanized antidisialoganglioside monoclonal antibody (hu14.18K322A) throughout therapy improves early response and outcomes in children with newly diagnosed high-risk neuroblastoma.Patients and methodsWe conducted a prospective, single-arm, three-stage, phase II clinical trial. Six cycles of induction chemotherapy were coadministered with hu14.18K322A, granulocyte-macrophage colony-stimulating factor (GM-CSF), and low-dose interleukin-2 (IL-2). The consolidation regimen included busulfan and melphalan. When available, an additional cycle of parent-derived natural killer cells with hu14.18K322A was administered during consolidation (n = 31). Radiation therapy was administered at the end of consolidation. Postconsolidation treatment included hu14.18K322A, GM-CSF, IL-2, and isotretinoin. Early response was assessed after the first two cycles of induction therapy. End-of-induction response, event-free survival (EFS), and overall survival (OS) were evaluated.ResultsSixty-four patients received hu14.18K322A with induction chemotherapy. This regimen was well tolerated, with continuous infusion narcotics. Partial responses (PRs) or better after the first two chemoimmunotherapy cycles occurred in 42 of 63 evaluable patients (66.7%; 95% CI, 55.0 to 78.3). Primary tumor volume decreased by a median of 75% (range, 100% [complete disappearance]-5% growth). Median peak hu14.18K322A serum levels in cycle one correlated with early response to therapy (P = .0154, one-sided t-test). Sixty of 62 patients (97%) had an end-of-induction partial response or better. No patients experienced progressive disease during induction. The 3-year EFS was 73.7% (95% CI, 60.0 to 83.4), and the OS was 86.0% (95% CI, 73.8 to 92.8), respectively.ConclusionAdding hu14.18K322A to induction chemotherapy improved early objective responses, significantly reduced tumor volumes in most patients, improved end-of-induction response rates, and yielded an encouraging 3-year EFS. These results, if validated in a larger study, may be practice changing.
- Published
- 2022
6. Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study
- Author
-
Venkatramani, Rajkumar, Xue, Wei, Randall, R Lor, Wolden, Suzanne, Anderson, James, Lopez-Terrada, Dolores, Black, Jennifer, Kao, Simon C, Shulkin, Barry, Ostrenga, Andrew, Pappo, Alberto, and Spunt, Sheri L
- Subjects
Clinical Trials and Supportive Activities ,Patient Safety ,Pediatric ,Orphan Drug ,Clinical Research ,Rare Diseases ,Cancer ,Pediatric Research Initiative ,Pediatric Cancer ,Evaluation of treatments and therapeutic interventions ,4.2 Evaluation of markers and technologies ,6.5 Radiotherapy and other non-invasive therapies ,Detection ,screening and diagnosis ,Adolescent ,Adult ,Child ,Child ,Preschool ,Combined Modality Therapy ,Female ,Follow-Up Studies ,Humans ,Infant ,Male ,Neoadjuvant Therapy ,Prognosis ,Prospective Studies ,Sarcoma ,Synovial ,Survival Rate ,Young Adult ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeSynovial sarcoma (SS) is the second most common malignant soft tissue tumor in children. ARST0332 evaluated a risk-based treatment strategy for young patients with soft tissue sarcoma designed to limit therapy for low-risk (LR) disease and to test neoadjuvant chemoradiotherapy for unresected higher-risk disease.MethodsNewly diagnosed patients with SS age < 30 years were assigned to four treatment arms based on disease features: A (surgery only), B (55.8 Gy radiotherapy [RT]), C (ifosfamide and doxorubicin [ID] chemotherapy plus 55.8 Gy RT), and D (neoadjuvant ID and 45 Gy RT, then surgery and RT boost based on margins followed by adjuvant ID). Patients treated in Arms A and B were considered LR, arms C and D without metastases as intermediate-risk (IR), and those with metastases as high-risk (HR).ResultsOf the 146 patients with SS enrolled, 138 were eligible and evaluable: LR (46), IR (71), and HR (21). Tumors were 80% extremity, 70% > 5 cm, 70% high-grade, 62% invasive, 95% deep, and 15% metastatic. Treatment was on arm A (29.7%), B (3.6%), C (16.7%), and D (50%). There were no toxic deaths and four unexpected grade 4 adverse events. By risk group, at a median follow-up of 6.8 years, estimated 5-year event-free survival was LR 82%, IR 70%, and HR 8%, and overall survival was LR 98%, IR 89%, and HR 13%. After accounting for the features that defined risk category, none of the other patient or disease characteristics (age, sex, tumor site, tumor invasiveness, and depth) improved the risk stratification model.ConclusionThe risk-based treatment strategy used in ARST0332 produced favorable outcomes in patients with nonmetastatic SS relative to historical controls despite using RT less frequently and at lower doses. The outcome for metastatic SS remains unsatisfactory and new therapies are urgently needed.
- Published
- 2021
7. Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults
- Author
-
Tinkle, Christopher L, Singh, Charu, Lloyd, Shane, Guo, Yian, Li, Yimei, Pappo, Alberto S, DuBois, Steven G, Lucas, John T, Haas-Kogan, Daphne A, Terezakis, Stephanie A, Braunstein, Steve E, and Krasin, Matthew J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Vaccine Related ,Pediatric ,Adolescent ,Adult ,Bone Neoplasms ,Child ,Child ,Preschool ,Confidence Intervals ,Disease Progression ,Female ,Humans ,Incidence ,Male ,Neoplasm Recurrence ,Local ,Progression-Free Survival ,Radiation Injuries ,Radiosurgery ,Radiotherapy Dosage ,Response Evaluation Criteria in Solid Tumors ,Sarcoma ,Statistics ,Nonparametric ,Survival Analysis ,Treatment Outcome ,Young Adult ,Other Physical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeThe use of stereotactic body radiation therapy (SBRT) in pediatric patients has been underreported. We reviewed practice patterns, outcomes, and toxicity of SBRT in this population.Methods and materialsIn this multi-institutional study, 55 patients with 107 non-central nervous system lesions treated with SBRT between 2010 and 2016 were reviewed. Treatment response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST v1.1 criteria for soft-tissue and bone lesions, respectively. Patterns of local failure (LF) were assessed dosimetrically. The cumulative incidence of LF and toxicity were estimated accounting for the competing risk event of death. Predictors of LF were identified through joint frailty models for clustered competing risks.ResultsThe median (range) dose/fraction was 7 (4.5-25) Gy, the total (range) dose/site was 35 (12-45), and the median (range) number of fractions was 5 (1-9). The radiographic response rates of bone and soft-tissue lesions were 90.6% and 76.7%, respectively. Symptom improvement was observed for 62% of symptomatic sites. A total of 27 LFs were documented, with 14 in-field, 9 marginal, and 4 out-of-field LFs. The 1-year estimated cumulative LF rate, progression-free survival, and overall survival were 25.2% (95% confidence interval [CI], 17.2%-36.1%), 17.5% (95% CI, 9.0%-34.1%), and 61% (95% CI, 48.9%-76.1%), respectively. Lesion type (soft tissue vs bone) was the only significant predictor of LF on multivariable analysis (P = .04), with increased hazard for soft-tissue lesions. No acute or late toxicity of grade 4 or higher was observed; the estimated 1-year cumulative incidence of late toxicity of any grade was 7.5% (95% CI, 3.6%-12.1%).ConclusionsThe SBRT was well tolerated and resulted in radiographic response and symptom palliation in most pediatric patients with advanced disease. The 1-year cumulative LF rate of 25% will serve as a benchmark for further modifications to radiation therapy indications, parameters, and combination therapy.
- Published
- 2021
8. Immune-related adverse events from immune checkpoint inhibitors in pediatric patients: A literature review and case series
- Author
-
Cupit-Link, Margaret, Khan, Raja, Pappo, Alberto, and Helmig, Sara
- Published
- 2023
- Full Text
- View/download PDF
9. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
- Author
-
Pearson, Andrew D.J., Federico, Sara, Gatz, Susanne A., Ortiz, Michael, Lesa, Giovanni, Scobie, Nicole, Gounaris, Ioannis, Weiner, Susan L., Weigel, Brenda, Unger, T.J., Stewart, Elizabeth, Smith, Malcolm, Slotkin, Emily K., Reaman, Gregory, Pappo, Alberto, Nysom, Karsten, Norga, Koen, McDonough, Joe, Marshall, Lynley V., Ludwinski, Donna, Ligas, Franca, Karres, Dominik, Kool, Marcel, Horner, Thierry J., Henssen, Anton, Heenen, Delphine, Hawkins, Douglas S., Gore, Lia, Bender, Julia Glade, Galluzzo, Sara, Fox, Elizabeth, de Rojas, Teresa, Davies, Barry R., Chakrabarti, Jayeta, Carmichael, Juliet, Bradford, Diana, Blanc, Patricia, Bernardi, Ronald, Benchetrit, Sylvie, Akindele, Korede, and Vassal, Gilles
- Published
- 2023
- Full Text
- View/download PDF
10. Cutaneous Melanoma in Children
- Author
-
Mansfield, Sara A., primary and Pappo, Alberto S., additional
- Published
- 2023
- Full Text
- View/download PDF
11. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers.
- Author
-
Amin, Hesham M, Morani, Ajaykumar C, Daw, Najat C, Lamhamedi-Cherradi, Salah-Eddine, Subbiah, Vivek, Menegaz, Brian A, Vishwamitra, Deeksha, Eskandari, Ghazaleh, George, Bhawana, Benjamin, Robert S, Patel, Shreyaskumar, Song, Juhee, Lazar, Alexander J, Wang, Wei-Lien, Kurzrock, Razelle, Pappo, Alberto, Anderson, Peter M, Schwartz, Gary K, Araujo, Dejka, Cuglievan, Branko, Ratan, Ravin, McCall, David, Mohiuddin, Sana, Livingston, John A, Molina, Eric R, Naing, Aung, and Ludwig, Joseph A
- Subjects
Ewing sarcoma ,PET/CT ,biological therapies ,biomarker ,drug response ,pIGF-1R ,PET ,CT ,Oncology and Carcinogenesis - Abstract
Background : Ten to fourteen percent of Ewing sarcoma (ES) study participants treated nationwide with IGF-1 receptor (IGF-1R)-targeted antibodies achieved tumor regression. Despite this success, low response rates and short response durations (approximately 7-weeks) have slowed the development of this therapy. Methods: We performed a meta-analysis of five phase-1b/2 ES-oriented trials that evaluated the anticancer activity of IGF-1R antibodies +/- mTOR inhibitors (mTORi). Our meta-analysis provided a head-to-head comparison of the clinical benefits of IGF-1R antibodies vs. the IGF-1R/mTOR-targeted combination. Available pretreatment clinical samples were semi-quantitatively scored using immunohistochemistry to detect proteins in the IGF-1R/PI3K/AKT/mTOR pathway linked to clinical response. Early PET/CT imaging, obtained within the first 2 weeks (median 10 days), were examined to determine if reduced FDG avidity was predictive of progression-free survival (PFS). Results: Among 56 ES patients treated at MD Anderson Cancer Center (MDACC) with IGF-1R antibodies, our analysis revealed a significant ~two-fold improvement in PFS that favored a combination of IGF-1R/mTORi therapy (1.6 vs. 3.3-months, p = 0.042). Low pIGF-1R in the pretreatment specimens was associated with treatment response. Reduced total-lesion glycolysis more accurately predicted the IGF-1R response than other previously reported radiological biomarkers. Conclusion: Synergistic drug combinations, and newly identified proteomic or radiological biomarkers of IGF-1R response, may be incorporated into future IGF-1R-related trials to improve the response rate in ES patients.
- Published
- 2020
12. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- Author
-
Hong, David S, DuBois, Steven G, Kummar, Shivaani, Farago, Anna F, Albert, Catherine M, Rohrberg, Kristoffer S, van Tilburg, Cornelis M, Nagasubramanian, Ramamoorthy, Berlin, Jordan D, Federman, Noah, Mascarenhas, Leo, Geoerger, Birgit, Dowlati, Afshin, Pappo, Alberto S, Bielack, Stefan, Doz, François, McDermott, Ray, Patel, Jyoti D, Schilder, Russell J, Tahara, Makoto, Pfister, Stefan M, Witt, Olaf, Ladanyi, Marc, Rudzinski, Erin R, Nanda, Shivani, Childs, Barrett H, Laetsch, Theodore W, Hyman, David M, and Drilon, Alexander
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Clinical Research ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Child ,Child ,Preschool ,Female ,Humans ,Infant ,Infant ,Newborn ,Male ,Middle Aged ,Neoplasms ,Proteins ,Pyrazoles ,Pyrimidines ,Young Adult ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundThe selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.MethodsPatients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).FindingsBetween May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [
- Published
- 2020
13. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study
- Author
-
Spunt, Sheri L, Million, Lynn, Chi, Yueh-Yun, Anderson, James, Tian, Jing, Hibbitts, Emily, Coffin, Cheryl, McCarville, M Beth, Randall, R Lor, Parham, David M, Black, Jennifer O, Kao, Simon C, Hayes-Jordan, Andrea, Wolden, Suzanne, Laurie, Fran, Speights, Roseanne, Kawashima, Ellen, Skapek, Stephen X, Meyer, William, Pappo, Alberto S, and Hawkins, Douglas S
- Subjects
Clinical Research ,Patient Safety ,Pediatric Cancer ,Cancer ,Digestive Diseases ,Rare Diseases ,Pediatric ,6.1 Pharmaceuticals ,6.5 Radiotherapy and other non-invasive therapies ,Evaluation of treatments and therapeutic interventions ,Adolescent ,Adult ,Antineoplastic Combined Chemotherapy Protocols ,Chemoradiotherapy ,Adjuvant ,Child ,Child ,Preschool ,Combined Modality Therapy ,Doxorubicin ,Female ,Follow-Up Studies ,Humans ,Ifosfamide ,Infant ,Infant ,Newborn ,Male ,Neoadjuvant Therapy ,Prognosis ,Prospective Studies ,Risk Factors ,Sarcoma ,Surgical Procedures ,Operative ,Survival Rate ,Young Adult ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundTumour grade, tumour size, resection potential, and extent of disease affect outcome in paediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), but no risk stratification systems exist and the standard of care is poorly defined. We developed a risk stratification system from known prognostic factors and assessed it in the context of risk-adapted therapy for young patients with NRSTS.MethodsIn this prospective study, eligible patients enrolled in 159 hospitals in three countries were younger than 30 years, had a Lansky (patients ≤16 years) or Karnofsky (patients >16 years) performance status score of at least 50, and a new diagnosis of a WHO (2002 criteria) intermediate (rarely metastasising) or malignant soft-tissue tumour (apart from tumour types eligible for other Children's Oncology Group studies and tumours for which the therapy in this trial was deemed inappropriate), malignant peripheral nerve sheath tumour, non-metastatic and grossly resected dermatofibrosarcoma protuberans, undifferentiated embryonal sarcoma of the liver, or unclassified malignant soft-tissue sarcoma. Each patient was assigned to one of three risk groups and one of four treatment groups. Risk groups were: low (non-metastatic R0 or R1 low-grade, or ≤5 cm R1 high-grade tumour); intermediate (non-metastatic R0 or R1 >5 cm high-grade, or unresected tumour of any size or grade); or high (metastatic tumour). The treatment groups were surgery alone, radiotherapy (55·8 Gy), chemoradiotherapy (chemotherapy and 55·8 Gy radiotherapy), and neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost based on margins with continued chemotherapy). Chemotherapy included six cycles of ifosfamide 3 g/m2 per dose intravenously on days 1-3 and five cycles of doxorubicin 37·5 mg/m2 per dose intravenously on days 1-2 every 3 weeks with sequence adjusted on the basis of timing of surgery or radiotherapy. The primary outcomes were event-free survival, overall survival, and the pattern of treatment failure. Analysis was done per protocol. This study has been completed and is registered with ClinicalTrials.gov, NCT00346164.FindingsBetween Feb 5, 2007, and Feb 10, 2012, 550 eligible patients were enrolled, of whom 21 were treated in the incorrect group and excluded from this analysis. 529 evaluable patients were included in the analysis: low-risk (n=222), intermediate-risk (n=227), high-risk (n=80); surgery alone (n=205), radiotherapy (n=17), chemoradiotherapy (n=111), and neoadjuvant chemoradiotherapy (n=196). At a median follow-up of 6·5 years (IQR 4·9-7·9), 5-year event-free survival and overall survival were: 88·9% (95% CI 84·0-93·8) and 96·2% (93·2-99·2) in the low-risk group; 65·0% (58·2-71·8) and 79·2% (73·4-85·0) in the intermediate-risk group; and 21·2% (11·4-31·1) and 35·5% (23·6-47·4) in the high-risk group, respectively. Risk group predicted event-free survival and overall survival (p
- Published
- 2020
14. Other Rare Tumors of the Skin and Subcutaneous Tissue
- Author
-
Pappo, Alberto, Ferrari, Andrea, Reaman, Gregory H., Series Editor, Smith, Franklin O., Series Editor, Schneider, Dominik T., editor, Brecht, Ines B., editor, Olson, Thomas A., editor, and Ferrari, Andrea, editor
- Published
- 2022
- Full Text
- View/download PDF
15. Cutaneous Melanoma
- Author
-
Indini, Alice, Pappo, Alberto S., Eigentler, Thomas K., Collini, Paola, Ferrari, Andrea, Reaman, Gregory H., Series Editor, Smith, Franklin O., Series Editor, Schneider, Dominik T., editor, Brecht, Ines B., editor, Olson, Thomas A., editor, and Ferrari, Andrea, editor
- Published
- 2022
- Full Text
- View/download PDF
16. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
- Author
-
Furman, Wayne L, Federico, Sara M, McCarville, Mary Beth, Shulkin, Barry L, Davidoff, Andrew M, Krasin, Matthew J, Sahr, Natasha, Sykes, April, Wu, Jianrong, Brennan, Rachel C, Bishop, Michael William, Helmig, Sara, Stewart, Elizabeth, Navid, Fariba, Triplett, Brandon, Santana, Victor M, Bahrami, Armita, Anthony, Gwendolyn, Yu, Alice L, Hank, Jacquelyn, Gillies, Stephen D, Sondel, Paul M, Leung, Wing H, and Pappo, Alberto S
- Subjects
Clinical Trials and Supportive Activities ,Neuroblastoma ,Rare Diseases ,Cancer ,Neurosciences ,Pediatric ,Pediatric Cancer ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adolescent ,Adult ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Child ,Disease-Free Survival ,Female ,Gangliosides ,Granulocyte-Macrophage Colony-Stimulating Factor ,Humans ,Induction Chemotherapy ,Kaplan-Meier Estimate ,Killer Cells ,Natural ,Male ,Progression-Free Survival ,Prospective Studies ,Young Adult ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeWe sought to evaluate whether combining a humanized antidisialoganglioside mAb (hu14.18K322A) with induction chemotherapy improves early responses and outcomes in children with newly diagnosed high-risk neuroblastoma.Patients and methodsWe conducted a prospective nonrandomized, single-arm, two-stage, phase II clinical trial. Six courses of induction chemotherapy were coadministered with hu14.18K322A and followed with granulocyte-macrophage colony-stimulating factor (GM-CSF) and low-dose IL2. Consolidation was performed with a busulfan/melphalan preparative regimen. An additional course of hu14.18K322A was administered with parent-derived natural killer cells, when available, during consolidation. Hu14.18K322A, GM-CSF, IL2, and isotretinoin were then administered. Secondary outcomes included reduced tumor volume and semiquantitative 123I-metaiodobenzylguanidine scoring [i.e., Curie scores (CS)] at the end of induction.ResultsForty-two patients received hu14.18K322A and induction chemotherapy. This regimen was well tolerated, with continuous-infusion narcotics adjusted to patient tolerance. Partial responses (PR) or better after the first two chemoimmunotherapy courses occurred in 32 patients [76.2%; 95% confidence interval (CI), 60.6-88.0]. This was accompanied by primary tumor volume reductions (median, -76%; range, -100% to 5%). Of 35 patients with stage IV disease who completed induction, 31 had end-of-induction CSs of 2 or less. No patients experienced progression during induction. Two-year event-free survival (EFS) was 85.7% (95% CI, 70.9-93.3).ConclusionsAdding hu14.18K322A to induction chemotherapy produced early PR or better in most patients, reduced tumor volumes, improved CSs at the end of induction, and yielded an encouraging 2-year EFS. These results, if validated in a larger study, may change the standard of care for children with high-risk neuroblastoma.
- Published
- 2019
17. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
- Author
-
Pearson, Andrew DJ., Allen, Carl, Fangusaro, Jason, Hutter, Caroline, Witt, Olaf, Weiner, Susan, Reaman, Gregory, Russo, Mark, Bandopadhayay, Pratiti, Ahsan, Sama, Barone, Amy, Barry, Elly, de Rojas, Teresa, Fisher, Michael, Fox, Elizabeth, Bender, Julia Glade, Gore, Lia, Hargrave, Darren, Hawkins, Doug, Kreider, Brent, Langseth, Abraham J., Lesa, Giovanni, Ligas, Franca, Marotti, Marcelo, Marshall, Lynley V., Nasri, Kahina, Norga, Koen, Nysom, Karsten, Pappo, Alberto, Rossato, Gianluca, Scobie, Nicole, Smith, Malcolm, Stieglitz, Elliot, Weigel, Brenda, Weinstein, Amy, Viana, Ruth, Karres, Dominik, and Vassal, Gilles
- Published
- 2022
- Full Text
- View/download PDF
18. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
- Author
-
DuBois, Steven G, Laetsch, Theodore W, Federman, Noah, Turpin, Brian K, Albert, Catherine M, Nagasubramanian, Ramamoorthy, Anderson, Megan E, Davis, Jessica L, Qamoos, Hope E, Reynolds, Mark E, Cruickshank, Scott, Cox, Michael C, Hawkins, Douglas S, Mascarenhas, Leo, and Pappo, Alberto S
- Subjects
Pediatric ,Rare Diseases ,Cancer ,Patient Safety ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Child ,Child ,Preschool ,Disease Progression ,Female ,Fibrosarcoma ,Humans ,Infant ,Infant ,Newborn ,Male ,Neoadjuvant Therapy ,Oncogene Proteins ,Fusion ,Pyrazoles ,Pyrimidines ,Receptor ,trkA ,Sarcoma ,Soft Tissue Neoplasms ,Treatment Outcome ,infantile fibrosarcoma ,larotrectinib ,local control ,neurotrophic receptor tyrosine kinase ,pediatric ,sarcoma ,surgery ,tropomyosin receptor kinase (TRK) fusion. ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
BackgroundThe highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who were treated preoperatively with larotrectinib and underwent subsequent surgical resection.MethodsA total of 24 children were treated on a pediatric phase 1 trial of larotrectinib (ClinicalTrials.gov identifier NCT02637687). Five children who had a documented TRK fusion sarcoma and underwent surgical resection were included in the current analysis. Tumor response (Response Evaluation Criteria In Solid Tumors [RECIST] version 1.1) and surgical outcomes were collected prospectively.ResultsA total of 5 patients (median age, 2 years; range, 0.4-12 years) had locally advanced infantile fibrosarcoma (3 patients) or soft-tissue sarcoma (2 patients). Four patients had disease that was refractory to standard therapy. All 5 patients achieved a partial response to larotrectinib by version 1.1 of RECIST and underwent surgical resection after a median of 6 cycles (range, 4-9 cycles) of treatment. Surgical resections were R0 (negative resection margins with no tumor at the inked resection margin) in 3 patients, R1 (microscopic residual tumor at the resection margin) in 1 patient, and R2 (macroscopic residual tumor at the resection margin) in 1 patient. Three patients achieved complete (2 patients) or near-complete (>98% treatment effect; 1 patient) pathologic responses. These patients remained in follow-up and were no longer receiving larotrectinib for a minimum of 7 to 15 months postoperatively. Two patients had viable tumor at the time of surgical resection and positive resection margins and continued to receive adjuvant larotrectinib. No patients experienced postoperative complications or wound healing issues.ConclusionsChildren with locally advanced TRK fusion sarcomas may proceed to surgical resection after treatment with the selective TRK inhibitor larotrectinib, thereby sparing them the potentially significant morbidity noted with current approaches. These results support the evaluation of larotrectinib as presurgical therapy in children with newly diagnosed TRK fusion sarcomas.
- Published
- 2018
19. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
- Author
-
Pearson, Andrew DJ., Gaspar, Nathalie, Janeway, Katherine, Campbell-Hewson, Quentin, Lawlor, Elizabeth R., Copland, Chris, Karres, Dominik, Norga, Koen, Benzaghou, Fawzi, Weiner, Susan, Weigel, Brenda, Weiss, Aaron R., Strauss, Sandra J., Smith, Malcolm, Setty, Bhuvana A., Seibel, Nita, Scobie, Nicole, Pappo, Alberto, Okpara, Chinyere E., Nysom, Karsten, McDonough, Joe, Marshall, Lynley V., Ludwinski, Donna, Ligas, Franca, Lesa, Giovanni, Knudsen, Steen, Kauh, John, Hsieh, Antony, Heenen, Delphine, Hawkins, Douglas S., Graham, Ann, Garmey, Edward, DuBois, Steven G., Fox, Elizabeth, Donoghue, Martha, de Rojas, Teresa, Chung, John, Casanova, Michela, Brennan, Bernadette, Bishop, Michael, Buenger, Vickie, Reaman, Gregory, and Vassal, Gilles
- Published
- 2022
- Full Text
- View/download PDF
20. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
- Author
-
Yang, James C. H., Brose, Marcia S., Castro, Gilberto, Kim, Edward S., Lassen, Ulrik N., Leyvraz, Serge, Pappo, Alberto, López-Ríos, Fernando, Reeves, John A., Fellous, Marc, Penault-Llorca, Frédérique, Rudzinski, Erin R., Tabatabai, Ghazaleh, Vassal, Gilles, Drilon, Alexander, and Trent, Jonathan
- Published
- 2022
- Full Text
- View/download PDF
21. Clinical features and outcomes of young patients with low‐grade non‐rhabdomyosarcoma soft tissue sarcomas treated with a risk‐based strategy: A report from Children's Oncology Group study ARST0332.
- Author
-
Douglass, David P., Coffin, Cheryl M., Randall, R. Lor, Yang, Yan, Barkauskas, Donald A., Million, Lynn, McCarville, M. Beth, Pappo, Alberto S., Weiss, Aaron R., and Spunt, Sheri L.
- Published
- 2024
- Full Text
- View/download PDF
22. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- Author
-
Laetsch, Theodore W, DuBois, Steven G, Mascarenhas, Leo, Turpin, Brian, Federman, Noah, Albert, Catherine M, Nagasubramanian, Ramamoorthy, Davis, Jessica L, Rudzinski, Erin, Feraco, Angela M, Tuch, Brian B, Ebata, Kevin T, Reynolds, Mark, Smith, Steven, Cruickshank, Scott, Cox, Michael C, Pappo, Alberto S, and Hawkins, Douglas S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Patient Safety ,Cancer ,Clinical Research ,Pediatric ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Administration ,Oral ,Adolescent ,Age Factors ,Antineoplastic Agents ,Biomarkers ,Tumor ,Child ,Child ,Preschool ,Discoidin Domain Receptor 2 ,Drug Administration Schedule ,Female ,Gene Fusion ,Humans ,Infant ,Male ,Membrane Glycoproteins ,Neoplasms ,Protein Kinase Inhibitors ,Pyrazoles ,Pyrimidines ,Receptor Protein-Tyrosine Kinases ,Receptor ,trkA ,Receptor ,trkB ,Time Factors ,Treatment Outcome ,United States ,Young Adult ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundGene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients.MethodsThis multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (
- Published
- 2018
23. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- Author
-
Drilon, Alexander, Laetsch, Theodore W, Kummar, Shivaani, DuBois, Steven G, Lassen, Ulrik N, Demetri, George D, Nathenson, Michael, Doebele, Robert C, Farago, Anna F, Pappo, Alberto S, Turpin, Brian, Dowlati, Afshin, Brose, Marcia S, Mascarenhas, Leo, Federman, Noah, Berlin, Jordan, El-Deiry, Wafik S, Baik, Christina, Deeken, John, Boni, Valentina, Nagasubramanian, Ramamoorthy, Taylor, Matthew, Rudzinski, Erin R, Meric-Bernstam, Funda, Sohal, Davendra PS, Ma, Patrick C, Raez, Luis E, Hechtman, Jaclyn F, Benayed, Ryma, Ladanyi, Marc, Tuch, Brian B, Ebata, Kevin, Cruickshank, Scott, Ku, Nora C, Cox, Michael C, Hawkins, Douglas S, Hong, David S, and Hyman, David M
- Subjects
Pediatric ,Patient Safety ,Cancer ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adolescent ,Adult ,Aged ,Antineoplastic Agents ,Child ,Child ,Preschool ,Disease-Free Survival ,Female ,Humans ,Infant ,Kaplan-Meier Estimate ,Male ,Middle Aged ,Neoplasms ,Oncogene Proteins ,Fusion ,Protein Kinases ,Pyrazoles ,Pyrimidines ,Receptor Protein-Tyrosine Kinases ,Young Adult ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundFusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.MethodsWe enrolled patients with consecutively and prospectively identified TRK fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults. The primary end point for the combined analysis was the overall response rate according to independent review. Secondary end points included duration of response, progression-free survival, and safety.ResultsA total of 55 patients, ranging in age from 4 months to 76 years, were enrolled and treated. Patients had 17 unique TRK fusion-positive tumor types. The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment. At 1 year, 71% of the responses were ongoing and 55% of the patients remained progression-free. The median duration of response and progression-free survival had not been reached. At a median follow-up of 9.4 months, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative. Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients. No patient discontinued larotrectinib owing to drug-related adverse events.ConclusionsLarotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913 , NCT02637687 , and NCT02576431 .).
- Published
- 2018
24. High-grade osteosarcoma arising from a clinically aggressive infantile fibrosarcoma
- Author
-
Furtado, Larissa V, primary, Santiago, Teresa, additional, Abramson, Zachary R, additional, Kacar, Marija, additional, Shi, Zonggao, additional, Koo, Selene C, additional, Ruiz, Robert E, additional, Mostafavi, Roya, additional, Krasin, Matthew J, additional, Shulkin, Barry, additional, Talbot, Lindsay J, additional, Pappo, Alberto S, additional, and Gartrell, Jessica, additional
- Published
- 2024
- Full Text
- View/download PDF
25. Alternative approaches to retroperitoneal lymph node dissection for paratesticular rhabdomyosarcoma
- Author
-
Mansfield, Sara A., Murphy, Andrew J., Talbot, Lindsay, Prajapati, Hasmukh, Maller, Vinod, Pappo, Alberto, Singhal, Sunil, Krasin, Matthew J., Davidoff, Andrew M., and Abdelhafeez, Abdelhafeez
- Published
- 2020
- Full Text
- View/download PDF
26. Radiation therapy dose escalation achieves high rates of local control with tolerable toxicity profile in pediatric and young adult patients with Ewing sarcoma.
- Author
-
Kacar, Marija, Nagel, Margaret B., Jia Liang, Yimei Li, Neel, Michael D., Lucas Jr., John T., McCarville, M. Beth, Santiago, Teresa, Pappo, Alberto S., and Krasin, Matthew J.
- Subjects
EWING'S sarcoma ,YOUNG adults ,RADIOTHERAPY ,RADIATION doses ,CANCER chemotherapy - Abstract
Background: Local control for patients with Ewing sarcoma (EWS) who present with large tumors are suboptimal when treated with standard radiation therapy (RT) doses of 54-55.8 Gy. The purpose of this study is to determine local control and toxicity of dose-escalated RT for tumors =8 cm (greatest diameter at diagnosis) in pediatric and young adult patients with EWS. Methods: Eligible patients =30 years old with newly diagnosed EWS =8 cm treated with definitive conformal or intensity modulated photon, or proton radiation therapy techniques were included. All patients in the study received dose-escalated RT doses. Outcomes included overall survival (OS), event-free survival (EFS), local failure rates, and toxicity. Results: Thirty-two patients were included, 20 patients presented with metastatic disease and 12 patients with localized disease. The median RT dose was 64.8 Gy (range, 59.4-69.4 Gy) with variability of doses to protect normal surrounding tissues. All patients received systemic chemotherapy. The 5-year OS and EFS for the cohort was 64.2% and 42%, respectively. The 5-year cumulative incidence of local failure was 6.6%. There were two combined local and distant failures with no isolated local failures. Twenty-nine patients experienced short term toxicity, 90% of those being radiation dermatitis. Twenty-seven patients experienced long-term toxicity, with only one experiencing grade 4 toxicity, a secondary malignancy after therapy. Conclusion: This study demonstrates that definitive RT for pediatric and young adult patients with EWS =8 cm provides high rates of local control, while maintaining a tolerable toxicity profile. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 Study
- Author
-
Tinkle, Christopher L., Pappo, Alberto, Wu, Jianrong, Mao, Shenghua, Hua, Chia-ho, Shulkin, Barry L., McCarville, M. Beth, Kaste, Sue C., Davidoff, Andrew M., Bahrami, Armita, Green, Daniel M., Ness, Kirsten K., Merchant, Thomas E., Spunt, Sheri L., and Krasin, Matthew J.
- Published
- 2020
- Full Text
- View/download PDF
28. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
- Author
-
Geoerger, Birgit, Kang, Hyoung Jin, Yalon-Oren, Michal, Marshall, Lynley V, Vezina, Catherine, Pappo, Alberto, Laetsch, Theodore W, Petrilli, Antonio S, Ebinger, Martin, Toporski, Jacek, Glade-Bender, Julia, Nicholls, Wayne, Fox, Elizabeth, DuBois, Steven G, Macy, Margaret E, Cohn, Susan L, Pathiraja, Kumudu, Diede, Scott J, Ebbinghaus, Scot, and Pinto, Navin
- Published
- 2020
- Full Text
- View/download PDF
29. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High‐Risk Melanoma
- Author
-
Navid, Fariba, Herzog, Cynthia E, Sandoval, John, Daryani, Vinay M, Stewart, Clinton F, Gattuso, Jami, Mandrell, Belinda, Phipps, Sean, Chemaitilly, Wassim, Sykes, April, Davidoff, Andrew M, Shulkin, Barry L, Bahrami, Armita, Furman, Wayne L, Mao, Shenghua, Wu, Jianrong, Schiff, Deborah, Rao, Bhaskar, and Pappo, Alberto
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Cancer ,Patient Safety ,Pediatric ,Vaccine Related ,Adolescent ,Adult ,Child ,Child ,Preschool ,Disease-Free Survival ,Female ,Humans ,Interferon alpha-2 ,Interferon-alpha ,Male ,Melanoma ,Polyethylene Glycols ,Recombinant Proteins ,Risk Factors ,Survival Rate ,Young Adult ,adjuvant therapy ,childhood ,high risk ,melanoma ,pegylated interferon ,pharmacokinetics ,Clinical Sciences ,Paediatrics and Reproductive Medicine ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Paediatrics - Abstract
BackgroundPegylated interferon α-2b (IFN α-2b) improves disease-free survival in adults with resected stage III melanoma. We conducted a study to determine the feasibility and safety of incorporating pegylated IFN α-2b as adjuvant therapy in the treatment of children and adolescents with high-risk melanoma. Pharmacokinetic studies of IFN α-2b and neuropsychological and quality of life (OL) assessments were performed.Patient and methodsEligible patients with resected American Joint Committee on Cancer Stage IIC, IIIA, and IIIB cutaneous melanoma received nonpegylated IFN α-2b 20 million units/m(2) /day intravenously 5 days per week for 4 weeks (induction) followed by pegylated IFN α-2b 1 μg/kg/dose weekly subcutaneously (SQ) for 48 weeks (maintenance).ResultsTwenty-three patients (15 females, median age 10 years) were enrolled. All patients completed induction therapy; five patients did not complete maintenance therapy either because of recurrent disease (n = 2) or toxicity (n = 3). The most common grade 3 and 4 toxicities of pegylated IFN α-2b were neutropenia (35%) and elevated liver transaminases (17%). The median nonpegylated IFN α-2b AUC0-∞ (5,026 pcg⋅hr/ml) was similar to adults. The median pegylated IFN α-2b exposure (48,480 pcg⋅hr/ml) was greater than the cumulative weekly exposure for nonpegylated IFN α-2b administered SQ three times per week (TIW). Validated measures demonstrated an improvement in QOL scores and no decline in psychological functioning over the course of therapy.ConclusionsPegylated IFN α-2b 1 μg/kg/dose SQ weekly as maintenance therapy in children and adolescents with high-risk melanoma is feasible with tolerable toxicity and appears to yield higher exposures than nonpegylated IFN α-2b administered SQ TIW.
- Published
- 2016
30. Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development
- Author
-
Pearson, Andrew D J, primary, de Rojas, Teresa, additional, Karres, Dominik, additional, Reaman, Gregory, additional, Scobie, Nicole, additional, Fox, Elizabeth, additional, Lesa, Giovanni, additional, Ligas, Franca, additional, Norga, Koen, additional, Nysom, Karsten, additional, Pappo, Alberto, additional, Weigel, Brenda, additional, Weiner, Susan L, additional, and Vassal, Gilles, additional
- Published
- 2023
- Full Text
- View/download PDF
31. Primary bone sarcoma with BCOR internal tandem duplication
- Author
-
Malik, Faizan, Zreik, Riyam T., Hedges, Dale J., Nakitandwe, Joy, Lee, Seungjae, Ward, Russell A., McCarville, M. Beth, Pappo, Alberto, and Bahrami, Armita
- Published
- 2020
- Full Text
- View/download PDF
32. Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
- Author
-
Stiles, Zachary E., Murphy, Andrew J., Anghelescu, Doralina L., Brown, Christina-Lin, Davidoff, Andrew M., Dickson, Paxton V., Glazer, Evan S., Bishop, Michael W., Furman, Wayne L., Pappo, Alberto S., Lucas, Jr., John T., and Deneve, Jeremiah L.
- Published
- 2020
- Full Text
- View/download PDF
33. Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
- Author
-
Flaherty, Lawrence E, Othus, Megan, Atkins, Michael B, Tuthill, Ralph J, Thompson, John A, Vetto, John T, Haluska, Frank G, Pappo, Alberto S, Sosman, Jeffrey A, Redman, Bruce G, Moon, James, Ribas, Antoni, Kirkwood, John M, and Sondak, Vernon K
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adolescent ,Adult ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Child ,Cisplatin ,Dacarbazine ,Female ,Humans ,Interferon alpha-2 ,Interferon-alpha ,Interferons ,Interleukin-2 ,Male ,Melanoma ,Middle Aged ,Recombinant Proteins ,Vinblastine ,Clinical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
PurposeHigh-dose interferon (IFN) for 1 year (HDI) is the US Food and Drug Administration-approved adjuvant therapy for patients with high-risk melanoma. Efforts to modify IFN dose and schedule have not improved efficacy. We sought to determine whether a shorter course of biochemotherapy would be more effective.Patients and methodsS0008 (S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma) was an Intergroup phase III trial that enrolled high-risk patients (stage IIIA-N2a through IIIC-N3), randomly assigning them to receive either HDI or biochemotherapy consisting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-α-2b) and granulocyte colony-stimulating factor given every 21 days for three cycles. Coprimary end points were relapse-free survival (RFS) and overall survival (OS).ResultsIn all, 432 patients were enrolled. Grade 3 and 4 adverse events occurred in 57% and 7% of HDI patients and 36% and 40% of biochemotherapy patients, respectively. At a median follow-up of 7.2 years, biochemotherapy improved RFS (hazard ratio [HR], 0.75; 95% CI, 0.58 to 0.97; P = .015), with a median RFS of 4.0 years (95% CI, 1.9 years to not reached [NR]) versus 1.9 years for HDI (95% CI, 1.2 to 2.8 years) and a 5-year RFS of 48% versus 39%. Median OS was not different (HR, 0.98; 95% CI, 0.74 to 1.31; P = .55), with a median OS of 9.9 years (95% CI, 4.62 years to NR) for biochemotherapy versus 6.7 years (95% CI, 4.5 years to NR) for HDI and a 5-year OS of 56% for both arms.ConclusionBiochemotherapy is a shorter, alternative adjuvant treatment for patients with high-risk melanoma that provides statistically significant improvement in RFS but no difference in OS and more toxicity compared with HDI.
- Published
- 2014
34. Targeting the DNA Repair Pathway in Ewing Sarcoma
- Author
-
Stewart, Elizabeth, Goshorn, Ross, Bradley, Cori, Griffiths, Lyra M, Benavente, Claudia, Twarog, Nathaniel R, Miller, Gregory M, Caufield, William, Freeman, Burgess B, Bahrami, Armita, Pappo, Alberto, Wu, Jianrong, Loh, Amos, Karlström, Åsa, Calabrese, Chris, Gordon, Brittney, Tsurkan, Lyudmila, Hatfield, M Jason, Potter, Philip M, Snyder, Scott E, Thiagarajan, Suresh, Shirinifard, Abbas, Sablauer, Andras, Shelat, Anang A, and Dyer, Michael A
- Subjects
Biological Sciences ,Orphan Drug ,Pediatric Research Initiative ,Genetics ,Cancer ,Pediatric Cancer ,Pediatric ,Rare Diseases ,Animals ,Benzimidazoles ,Camptothecin ,Cell Death ,Cell Line ,Tumor ,DNA Breaks ,Double-Stranded ,DNA Repair ,Dacarbazine ,Drug Synergism ,Enzyme Inhibitors ,Irinotecan ,Mice ,Nude ,Molecular Targeted Therapy ,Phthalazines ,Piperazines ,Poly(ADP-ribose) Polymerase Inhibitors ,Poly(ADP-ribose) Polymerases ,Sarcoma ,Ewing ,Temozolomide ,Xenograft Model Antitumor Assays ,Biochemistry and Cell Biology ,Medical Physiology ,Biological sciences - Abstract
Ewing sarcoma (EWS) is a tumor of the bone and soft tissue that primarily affects adolescents and young adults. With current therapies, 70% of patients with localized disease survive, but patients with metastatic or recurrent disease have a poor outcome. We found that EWS cell lines are defective in DNA break repair and are sensitive to PARP inhibitors (PARPis). PARPi-induced cytotoxicity in EWS cells was 10- to 1,000-fold higher after administration of the DNA-damaging agents irinotecan or temozolomide. We developed an orthotopic EWS mouse model and performed pharmacokinetic and pharmacodynamic studies using three different PARPis that are in clinical development for pediatric cancer. Irinotecan administered on a low-dose, protracted schedule previously optimized for pediatric patients was an effective DNA-damaging agent when combined with PARPis; it was also better tolerated than combinations with temozolomide. Combining PARPis with irinotecan and temozolomide gave complete and durable responses in more than 80% of the mice.
- Published
- 2014
35. Is there a role for salvage re-irradiation in pediatric patients with locoregional recurrent rhabdomyosarcoma? Clinical outcomes from a multi-institutional cohort
- Author
-
Wakefield, Daniel V., Eaton, Bree R., Dove, Austin P.H., Hsu, Chih-Yang, Merchant, Thomas E., Pappo, Alberto, Davidoff, Andrew M., Esiashvili, Natia, Krasin, Matthew J., and Lucas, John T., Jr.
- Published
- 2018
- Full Text
- View/download PDF
36. Novel MED15::ATF1 fusion in a pediatric melanoma with spitzoid features and aggressive presentation.
- Author
-
Furtado, Larissa V., Cardenas, Maria, Santiago, Teresa, Ruiz, Robert E., Shi, Zonggao, Pappo, Alberto, and Kacar, Marija
- Published
- 2024
- Full Text
- View/download PDF
37. Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
- Author
-
Pearson, Andrew D J, Rojas, Teresa de, Karres, Dominik, Reaman, Gregory, Scobie, Nicole, Fox, Elizabeth, Lesa, Giovanni, Ligas, Franca, Norga, Koen, Nysom, Karsten, Pappo, Alberto, Weigel, Brenda, Weiner, Susan L, and Vassal, Gilles
- Subjects
DRUG development ,ANTINEOPLASTIC agents ,FORUMS ,PEDIATRICS ,PARTICIPATION - Abstract
In a landscape of an increasing number of products and histology and age agnostic trials for rare patient cancer, prioritization of products is required. Paediatric Strategy Forums, organized by ACCELERATE and the European Medicines Agency with participation of the US Food and Drug Administration, are multi-stakeholder meetings that share information to best inform pediatric drug development strategies and subsequent clinical trial decisions. Academia, industry, regulators, and patient advocates are equal members, with patient advocates highlighting unmet needs of children and adolescents with cancer. The 11 Paediatric Strategy Forums since 2017 have made specific and general conclusions to accelerate drug development. Conclusions on product prioritization meetings, as well as global master protocols, have been outputs of these meetings. Forums have provided information for regulatory discussions and decisions by industry to facilitate development of high-priority products; for example, 62% of high-priority assets (agreed at a Forum) in contrast to 5% of those assets not considered high priority have been the subject of a Paediatric Investigational Plan or Written Request. Where there are multiple products of the same class, Forums have recommended a focused and sequential approach. Class prioritization resulted in an increase in waivers for non-prioritized B-cell products (44% to 75%) and a decrease in monotherapy trials, proposed in Paediatric Investigation Plans (PIP) submissions of checkpoint inhibitors from 53% to 19%. Strategy Forums could play a role in defining unmet medical needs. Multi-stakeholder forums, such as the Paediatric Strategy Forum, serve as a model to improve collaboration in the oncology drug development paradigm. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
- Author
-
Bhatia, Smita, primary, Pappo, Alberto S., additional, Acquazzino, Melissa, additional, Allen-Rhoades, Wendy A., additional, Barnett, Marie, additional, Borinstein, Scott C., additional, Casey, Robert, additional, Choo, Sun, additional, Chugh, Rashmi, additional, Dinner, Shira, additional, Ermoian, Ralph, additional, Fair, Douglas, additional, Federman, Noah, additional, Folbrecht, Jeanelle, additional, Gandhi, Shipra, additional, Germann, Julie, additional, Goldsby, Robert, additional, Hayashi, Robert, additional, Huang, Alex Y., additional, Huang, Mary S., additional, Jacobs, Linda A., additional, Lee-Miller, Cathy, additional, Link, Michael P., additional, Livingston, John A., additional, Lustberg, Maryam, additional, Malogolowkin, Marcio, additional, Oeffinger, Kevin C., additional, Pratilas, Christine A., additional, Reed, Damon, additional, Skiles, Jodi, additional, von Mehren, Margaret, additional, Yeager, Nicholas, additional, Montgomery, Sarah, additional, and Hang, Lisa, additional
- Published
- 2023
- Full Text
- View/download PDF
39. Pediatric Oncology
- Author
-
Helmig, Sara E., primary and Pappo, Alberto, additional
- Published
- 2020
- Full Text
- View/download PDF
40. Malignant Melanoma in the Adolescent and Young Adult (AYA) Population
- Author
-
Davar, Diwakar, Bahrami, Armita, Pappo, Alberto S., Kirkwood, John M., Reaman, Gregory H., Series editor, Smith, Franklin O., Series editor, Bleyer, Archie, editor, Barr, Ronald, editor, Ries, Lynn, editor, Whelan, Jeremy, editor, and Ferrari, Andrea, editor
- Published
- 2017
- Full Text
- View/download PDF
41. Xenotransplantation of pre-pubertal ovarian cortex and prevention of follicle depletion with anti-Müllerian hormone (AMH)
- Author
-
Detti, Laura, Fletcher, Nicole M., Saed, Ghassan M., Sweatman, Trevor W., Uhlmann, Rebecca A., Pappo, Alberto, and Peregrin-Alvarez, Irene
- Published
- 2018
- Full Text
- View/download PDF
42. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
- Author
-
Geoerger, Birgit, Bergeron, Christophe, Gore, Lia, Sender, Leonard, Dunkel, Ira J., Herzog, Cynthia, Brochez, Lieve, Cruz, Ofelia, Nysom, Karsten, Berghorn, Elmer, Simsek, Burcin, Shen, Jun, and Pappo, Alberto
- Published
- 2017
- Full Text
- View/download PDF
43. Feasibility of indocyanine green‐guided localization of pulmonary nodules in children with solid tumors
- Author
-
Abdelhafeez, Abdelhafeez H., primary, Mothi, Suraj Sarvode, additional, Pio, Luca, additional, Mori, Motomi, additional, Santiago, Teresa C., additional, McCarville, M. Beth, additional, Kaste, Sue C., additional, Pappo, Alberto S., additional, Talbot, Lindsay J., additional, Murphy, Andrew J., additional, and Davidoff, Andrew M., additional
- Published
- 2023
- Full Text
- View/download PDF
44. Germline genomic findings in children and young adults with melanocytic tumors
- Author
-
Nagel, Margaret B., primary, Perrino, Melissa R., additional, Nuccio, Regina, additional, Blake, Alise K., additional, Harrison, Lynn, additional, Nichols, Kim E., additional, and Pappo, Alberto S., additional
- Published
- 2023
- Full Text
- View/download PDF
45. Data from Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing
- Author
-
Newman, Scott, primary, Nakitandwe, Joy, primary, Kesserwan, Chimene A., primary, Azzato, Elizabeth M., primary, Wheeler, David A., primary, Rusch, Michael, primary, Shurtleff, Sheila, primary, Hedges, Dale J., primary, Hamilton, Kayla V., primary, Foy, Scott G., primary, Edmonson, Michael N., primary, Thrasher, Andrew, primary, Bahrami, Armita, primary, Orr, Brent A., primary, Klco, Jeffery M., primary, Gu, Jiali, primary, Harrison, Lynn W., primary, Wang, Lu, primary, Clay, Michael R., primary, Ouma, Annastasia, primary, Silkov, Antonina, primary, Liu, Yanling, primary, Zhang, Zhaojie, primary, Liu, Yu, primary, Brady, Samuel W., primary, Zhou, Xin, primary, Chang, Ti-Cheng, primary, Pande, Manjusha, primary, Davis, Eric, primary, Becksfort, Jared, primary, Patel, Aman, primary, Wilkinson, Mark R., primary, Rahbarinia, Delaram, primary, Kubal, Manish, primary, Maciaszek, Jamie L., primary, Pastor, Victor, primary, Knight, Jay, primary, Gout, Alexander M., primary, Wang, Jian, primary, Gu, Zhaohui, primary, Mullighan, Charles G., primary, McGee, Rose B., primary, Quinn, Emily A., primary, Nuccio, Regina, primary, Mostafavi, Roya, primary, Gerhardt, Elsie L., primary, Taylor, Leslie M., primary, Valdez, Jessica M., primary, Hines-Dowell, Stacy J., primary, Pappo, Alberto S., primary, Robinson, Giles, primary, Johnson, Liza-Marie, primary, Pui, Ching-Hon, primary, Ellison, David W., primary, Downing, James R., primary, Zhang, Jinghui, primary, and Nichols, Kim E., primary
- Published
- 2023
- Full Text
- View/download PDF
46. Supplementary Tables S1-S5 from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment
- Author
-
Brady, Samuel W., primary, Ma, Xiaotu, primary, Bahrami, Armita, primary, Satas, Gryte, primary, Wu, Gang, primary, Newman, Scott, primary, Rusch, Michael, primary, Putnam, Daniel K., primary, Mulder, Heather L., primary, Yergeau, Donald A., primary, Edmonson, Michael N., primary, Easton, John, primary, Alexandrov, Ludmil B., primary, Chen, Xiang, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Downing, James R., primary, Pappo, Alberto S., primary, Raphael, Benjamin J., primary, Dyer, Michael A., primary, and Zhang, Jinghui, primary
- Published
- 2023
- Full Text
- View/download PDF
47. Supplementary Figure S2 from Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing
- Author
-
Newman, Scott, primary, Nakitandwe, Joy, primary, Kesserwan, Chimene A., primary, Azzato, Elizabeth M., primary, Wheeler, David A., primary, Rusch, Michael, primary, Shurtleff, Sheila, primary, Hedges, Dale J., primary, Hamilton, Kayla V., primary, Foy, Scott G., primary, Edmonson, Michael N., primary, Thrasher, Andrew, primary, Bahrami, Armita, primary, Orr, Brent A., primary, Klco, Jeffery M., primary, Gu, Jiali, primary, Harrison, Lynn W., primary, Wang, Lu, primary, Clay, Michael R., primary, Ouma, Annastasia, primary, Silkov, Antonina, primary, Liu, Yanling, primary, Zhang, Zhaojie, primary, Liu, Yu, primary, Brady, Samuel W., primary, Zhou, Xin, primary, Chang, Ti-Cheng, primary, Pande, Manjusha, primary, Davis, Eric, primary, Becksfort, Jared, primary, Patel, Aman, primary, Wilkinson, Mark R., primary, Rahbarinia, Delaram, primary, Kubal, Manish, primary, Maciaszek, Jamie L., primary, Pastor, Victor, primary, Knight, Jay, primary, Gout, Alexander M., primary, Wang, Jian, primary, Gu, Zhaohui, primary, Mullighan, Charles G., primary, McGee, Rose B., primary, Quinn, Emily A., primary, Nuccio, Regina, primary, Mostafavi, Roya, primary, Gerhardt, Elsie L., primary, Taylor, Leslie M., primary, Valdez, Jessica M., primary, Hines-Dowell, Stacy J., primary, Pappo, Alberto S., primary, Robinson, Giles, primary, Johnson, Liza-Marie, primary, Pui, Ching-Hon, primary, Ellison, David W., primary, Downing, James R., primary, Zhang, Jinghui, primary, and Nichols, Kim E., primary
- Published
- 2023
- Full Text
- View/download PDF
48. Data from St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem
- Author
-
McLeod, Clay, primary, Gout, Alexander M., primary, Zhou, Xin, primary, Thrasher, Andrew, primary, Rahbarinia, Delaram, primary, Brady, Samuel W., primary, Macias, Michael, primary, Birch, Kirby, primary, Finkelstein, David, primary, Sunny, Jobin, primary, Mudunuri, Rahul, primary, Orr, Brent A., primary, Treadway, Madison, primary, Davidson, Bob, primary, Ard, Tracy K., primary, Chiao, Arthur, primary, Swistak, Andrew, primary, Wiggins, Stephanie, primary, Foy, Scott, primary, Wang, Jian, primary, Sioson, Edgar, primary, Wang, Shuoguo, primary, Michael, J. Robert, primary, Liu, Yu, primary, Ma, Xiaotu, primary, Patel, Aman, primary, Edmonson, Michael N., primary, Wilkinson, Mark R., primary, Frantz, Andrew M., primary, Chang, Ti-Cheng, primary, Tian, Liqing, primary, Lei, Shaohua, primary, Islam, S.M. Ashiqul, primary, Meyer, Christopher, primary, Thangaraj, Naina, primary, Tater, Pamella, primary, Kandali, Vijay, primary, Ma, Singer, primary, Nguyen, Tuan, primary, Serang, Omar, primary, McGuire, Irina, primary, Robison, Nedra, primary, Gentry, Darrell, primary, Tang, Xing, primary, Palmer, Lance E., primary, Wu, Gang, primary, Suh, Ed, primary, Tanner, Leigh, primary, McMurry, James, primary, Lear, Matthew, primary, Pappo, Alberto S., primary, Wang, Zhaoming, primary, Wilson, Carmen L., primary, Cheng, Yong, primary, Meshinchi, Soheil, primary, Alexandrov, Ludmil B., primary, Weiss, Mitchell J., primary, Armstrong, Gregory T., primary, Robison, Leslie L., primary, Yasui, Yutaka, primary, Nichols, Kim E., primary, Ellison, David W., primary, Bangur, Chaitanya, primary, Mullighan, Charles G., primary, Baker, Suzanne J., primary, Dyer, Michael A., primary, Miller, Geralyn, primary, Newman, Scott, primary, Rusch, Michael, primary, Daly, Richard, primary, Perry, Keith, primary, Downing, James R., primary, and Zhang, Jinghui, primary
- Published
- 2023
- Full Text
- View/download PDF
49. Supplementary Figures S1-S11 from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment
- Author
-
Brady, Samuel W., primary, Ma, Xiaotu, primary, Bahrami, Armita, primary, Satas, Gryte, primary, Wu, Gang, primary, Newman, Scott, primary, Rusch, Michael, primary, Putnam, Daniel K., primary, Mulder, Heather L., primary, Yergeau, Donald A., primary, Edmonson, Michael N., primary, Easton, John, primary, Alexandrov, Ludmil B., primary, Chen, Xiang, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Downing, James R., primary, Pappo, Alberto S., primary, Raphael, Benjamin J., primary, Dyer, Michael A., primary, and Zhang, Jinghui, primary
- Published
- 2023
- Full Text
- View/download PDF
50. Data from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment
- Author
-
Brady, Samuel W., primary, Ma, Xiaotu, primary, Bahrami, Armita, primary, Satas, Gryte, primary, Wu, Gang, primary, Newman, Scott, primary, Rusch, Michael, primary, Putnam, Daniel K., primary, Mulder, Heather L., primary, Yergeau, Donald A., primary, Edmonson, Michael N., primary, Easton, John, primary, Alexandrov, Ludmil B., primary, Chen, Xiang, primary, Mardis, Elaine R., primary, Wilson, Richard K., primary, Downing, James R., primary, Pappo, Alberto S., primary, Raphael, Benjamin J., primary, Dyer, Michael A., primary, and Zhang, Jinghui, primary
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.